View More Recent Stories

Dec 27, 2024 04:05PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
Dec 25, 2024 11:32PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
Dec 25, 2024 08:01AM SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
Dec 23, 2024 10:16AM Humacyte (HUMA) PT Raised to $17 at Benchmark Following FDA approval for SYMVESS
Dec 23, 2024 09:24AM INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
Dec 22, 2024 07:21PM ROSEN, LEADING TRIAL ATTORNEYS, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
Dec 21, 2024 07:20PM ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
Dec 20, 2024 06:43AM Humacyte (HUMA) PT Raised to $15 at H.C. Wainwright
Dec 20, 2024 06:26AM BTIG Reiterates Buy Rating on Humacyte (HUMA)
Dec 19, 2024 10:48PM Humacyte (HUMA) Announces FDA Approval of SYMVESS
Dec 18, 2024 06:50PM Humacyte's (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles - Hagens Berman
Dec 17, 2024 05:50PM ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
Dec 16, 2024 09:07PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
Dec 16, 2024 05:49PM ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
Dec 15, 2024 09:02PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
Dec 15, 2024 08:28AM DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
Dec 14, 2024 09:02PM ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
Dec 13, 2024 09:01PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
Dec 13, 2024 08:00PM HUMA INVESTOR ALERT: Kirby McInerney LLP Notifies Humacyte, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
Dec 12, 2024 09:01PM ROSEN, A LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
Dec 11, 2024 09:00PM ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
Dec 11, 2024 05:20PM Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations - Hagens Berman
Nov 21, 2024 08:03AM Humacyte (HUMA) Clinical Results Highlighting Benefit of the ATEV in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
Nov 14, 2024 08:06AM Humacyte (HUMA) Announces Pricing of $15.0 Million Registered Direct Offering
Nov 8, 2024 08:02AM Humacyte, Inc. (HUMA) Misses Q3 EPS by 8c
Nov 5, 2024 06:43AM Humacyte (HUMA) PT Raised to $12 at H.C. Wainwright
Oct 28, 2024 07:01AM Humacyte (HUMA) Announces Presentation of Positive Results from V007 Phase 3 AV Access Trial
Oct 18, 2024 08:20AM TD Cowen Reiterates Buy Rating on Humacyte (HUMA)
Oct 18, 2024 07:51AM Piper Sandler Reiterates Neutral Rating on Humacyte (HUMA)
Oct 18, 2024 05:41AM BTIG Reiterates Buy Rating on Humacyte (HUMA)
Oct 7, 2024 08:19AM TD Cowen Reiterates Buy Rating on Humacyte (HUMA)
Oct 4, 2024 08:01AM Humacyte (HUMA) Prices 6.58M Share and Warrant Offering at $5.28/sh
Sep 30, 2024 02:54PM TD Cowen Reiterates Buy Rating on Humacyte (HUMA)
Sep 19, 2024 08:02AM Humacyte (HUMA) Announces Allowance of U.S. Patent Covering BioVascular Pancreas
Sep 9, 2024 07:03AM EF Hutton Starts Humacyte (HUMA) at Buy
Sep 5, 2024 07:23AM Benchmark Reiterates Buy Rating on Humacyte (HUMA)
Aug 27, 2024 11:08AM TD Cowen Reiterates Buy Rating on Humacyte (HUMA)
Aug 27, 2024 08:09AM Humacyte (HUMA) Presents Positive Long-Term Results of ATEV in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program
Aug 13, 2024 09:50AM Humacyte (HUMA) PT Lowered to $10 at BTIG
Aug 13, 2024 07:12AM Humacyte, Inc. (HUMA) Misses Q2 EPS by 24c
Aug 9, 2024 04:05PM Humacyte (HUMA) Announces FDA Communication of Additional Time Required to Complete Review of ATEV BLA
Jul 31, 2024 07:02AM Humacyte (HUMA) Reports ATEV Meets Primary Endpoints in V007 Phase 3 Trial
Jul 16, 2024 08:01AM Humacyte (HUMA) Appoints John P. Bamforth and Keith Anthony Jones to its Board
Jul 9, 2024 10:08AM Humacyte (HUMA) and Pluristyx Enter License Agreement to Develop BioVascular Pancreas using iPSCs
Jul 1, 2024 08:05AM Humacyte (HUMA) Acellular Tissue Engineered Vessel Receives FDA’s RMAT Designation for Patients with Advanced PAD
Jun 25, 2024 02:40PM TD Cowen Reiterates Buy Rating on Humacyte (HUMA)
Jun 17, 2024 03:12PM Humacyte (HUMA) PT Raised to $7.50 at TD Cowen
Jun 17, 2024 08:06AM Humacyte (HUMA): Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel
View More Recent Stories